GLP-1 Drugs and Opioid Use Disorder: What a New Safety Study Found

Why Are Researchers Studying GLP-1 Receptor Agonists in Opioid Use Disorder?

GLP-1 receptors are not confined to the pancreas and gut. They are also expressed in mesolimbic reward circuitry — the ventral tegmental area and nucleus accumbens — the same dopaminergic pathways implicated in drug reinforcement and craving. Preclinical work over the past decade has repeatedly shown that GLP-1 receptor agonism can blunt self-administration and cue-induced reinstatement of several drugs of abuse in rodent models, including opioids, prompting a wave of interest in whether the same pharmacology translates into human substance-use outcomes.[1]

Before any prospective efficacy trial can be run at scale, researchers need a basic safety picture: is it safe to prescribe a GLP-1 receptor agonist — approved for type 2 diabetes or obesity — to someone who also has opioid use disorder (OUD), a population with its own elevated psychiatric and gastrointestinal comorbidity burden? A target trial emulation published in Diabetes, Obesity and Metabolism in August 2026 is one of the first studies to answer that question directly using real-world prescribing data, rather than a curated trial population.[1][2]

What Did This New Target Trial Emulation Actually Analyse?

Researchers led by Hussain and colleagues used the MarketScan Commercial Claims and Encounters database, covering US insurance claims from 2016 to 2023, to build a target trial emulation — a design that applies the pre-specification rigour of a randomised trial (defined eligibility, treatment and comparator groups, follow-up windows, and outcomes declared in advance) to observational claims data.[1]

This is a safety study of prescribed pharmaceutical GLP-1 receptor agonists — approved medicines such as semaglutide and liraglutide — used off-label-adjacent in people who happen to have OUD. It is not a trial of GLP-1 drugs as an addiction treatment, and it says nothing directly about investigational multi-receptor agonists such as retatrutide, which have not been studied in this population.

What Safety Outcomes Did Researchers Track?

The investigators pre-specified ten safety outcomes spanning three domains: gastrointestinal and metabolic (including pancreatitis and gastroparesis), renal and respiratory events, and six psychiatric outcomes — anxiety, depression, stress-related disorders, eating disorders, insomnia, and suicidal behaviour or ideation.[1] Tracking psychiatric outcomes specifically was a deliberate design choice: regulators and clinicians have raised questions about a possible psychiatric signal with GLP-1 receptor agonists more broadly, and an OUD population already carries substantially elevated baseline rates of anxiety, depression and suicidality, which makes teasing apart any drug-attributable signal from background risk especially difficult without a matched comparator group.

Did GLP-1 Use Increase Any Risk in This Population?

Across the matched cohorts, GLP-1 receptor agonist initiation was not associated with an increased risk for any of the gastrointestinal, renal, respiratory, or psychiatric outcomes tracked.[1] Specifically, the authors reported no elevated risk for gastroparesis, and no increase across any of the six psychiatric categories, including depression, stress-related disorders, eating disorders, or suicidal behaviour or ideation.[1]

Which Risks Were Actually Lower With GLP-1 Use?

Beyond simply showing no excess harm, the study found GLP-1 initiators had a lower risk than non-initiators for three specific outcomes: pancreatitis, insomnia, and anxiety.[1] The authors did not report this as evidence that GLP-1 receptor agonists treat these conditions in people with OUD — an observational claims analysis cannot establish that kind of causal, treatment-level claim — but as a reassuring safety finding for clinicians weighing whether to prescribe a GLP-1 drug to a patient who also carries an OUD diagnosis.

What Are the Limitations of This Study?

Claims data cannot fully capture unmeasured confounding: people prescribed a GLP-1 receptor agonist while managing an OUD diagnosis may differ systematically from non-initiators in ways that propensity-score matching cannot completely correct for, including engagement with care, socioeconomic factors, and severity of underlying metabolic or substance-use disease. The study also could not verify medication adherence beyond pharmacy fills, and outcomes were identified using diagnosis codes rather than clinical adjudication.

Just as importantly, this is a safety study, not an efficacy study. It says nothing about whether GLP-1 receptor agonists reduce opioid craving, use, or relapse — only that, in this matched claims-based comparison, starting one did not appear to add measurable psychiatric or gastrointestinal risk on top of what people with OUD already carry.[1]

How Does This Fit the Broader GLP-1 and Substance-Use Research Picture?

This safety study lands alongside a small but growing observational literature on GLP-1 receptor agonists and substance use. A separate 2025 cohort analysis in Addiction examined GLP-1 and GIP receptor agonist prescriptions against substance-related outcomes in patients with opioid and alcohol use disorders, part of the same broader effort to characterise this drug class's behaviour in populations rarely included in the original diabetes and obesity trials.[3] Prospective, purpose-built trials are now the next step: a randomised, double-blind, placebo-controlled trial at Vanderbilt University is currently enrolling to test whether a GLP-1 receptor agonist reduces cue-elicited craving in OUD, using ecological momentary assessment as a primary endpoint — a study specifically designed to test efficacy, which this safety analysis was not.

It also sits alongside our recent coverage of a JAHA target trial emulation on GLP-1 use in obesity with autoimmune disease, part of a wider pattern in 2026 of large claims-based emulation studies mapping this drug class's real-world safety profile across populations well outside its original approval indications.

None of this changes the regulatory position of research-use peptides in the UK. GLP-1, GIP and glucagon receptor pharmacology remains an active preclinical and translational research area, and Velox Peptides supplies retatrutide — an investigational triple agonist across all three of these receptor pathways — strictly as an HPLC-verified in vitro research reagent, with batch documentation available on request and no dosing guidance or human-use claims of any kind. See our guide on whether research peptides are legal in the UK for the underlying regulatory framework.

This article discusses licensed pharmaceutical GLP-1 receptor agonists reported on in a third-party academic study; it makes no claims about Velox Peptides products. Where supplied by Velox Peptides, retatrutide is a research reagent, not a medicine, and has not been evaluated by the MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions